Overcoming Patient Barriers in Glycemic Control: Clinical Advances in Combination GLP-1 and Insulin Therapy

This activity is supported by an educational grant from

sanofi-aventis U.S.

Overcoming Patient Barriers in Glycemic Control: Clinical Advances in Combination GLP-1 and Insulin Therapy

Faculty

Eden Miller, DO

High Lakes Health Care Executive Director and Co-founder,

Diabetes Nation

Bend, Oregon

Jennifer Costello, PharmD, BCPS, BC-ADM

Assistant Director of Clinical Services for the Pharmacy Department

PGY-1 Residency Program Director

Saint Barnabas Medical Center

Livingston, New Jersey

Educational Objectives

After completing this continuing education program, the participant will be able to:

• Examine the glycemic control treatment gap in patients with type 2 diabetes and the factors that contribute to poor glycemic control
• Explain the use of combination regimens as initial treatment of type 2 diabetes to improve glycemic control
• Analyze the efficacy and safety of prandial insulin and glucagon-like peptide-1 (GLP-1) receptor agonists (both short-and long-acting) in combination with basal insulin, including the use of injectable coformulations
• Explore the role of the pharmacist in collaborating with clinicians and educating patients about GLP-1 agonists in combination with basal insulin and measures taken to decrease diabetic complications and promote adherence

Target audience: Retail P

harmacists

Type of activity: Application

Release date: June 12, 2016

Expiration date: June 12, 2017

Estimated time to complete activity: 2.0 hours

Fee: Free

Pharmacy Times Continuing Education is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 2.0 contact hours (0.2 CEUs) under the ACPE universal activity number 0290-0000-16-079-H01-P. The activity is available for CE credit through June 12, 2017.